Analysis of relapse-associated alternative mRNA splicing and construction of a prognostic signature predicting relapse in I–III colon cancer

• Published in: Genomics (San Diego, Calif.) Vol. 112; no. 6; pp. 4032 - 4040
• Main Authors: Zhang, Zhiyuan, Feng, Qingyang, Jia, Caiwei, Zheng, Peng, Lv, Yang, Mao, Yihao, Xu, Yuqiu, He, Guodong, Xu, Jianmin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2020
• Subjects: Alternative-splicing events; Colon cancer; Relapse; Alternative-splicing events; Relapse; Colon cancer
• ISSN: 0888-7543; 1089-8646
• DOI: 10.1016/j.ygeno.2020.07.002

The literature comprehensively analyzed alternative splicing (AS) events in colon cancer is little and corresponding prognostic signature is still a lack. Based on data of TCGA, the relapse-associated ASs were comprehensively analyzed and a signature was further constructed to predict the relapse in I–III colon cancer. In total 1912 ASs of 1384 mRNA were identified as relapse-associated ASs, protein-protein interactions (PPI) and ASs-splicing factors (SF) interactions network were identified. We finally built a robust signature to predict the relapse of I–III colon cancer with a considerable AUC value in both the training group and the test group. The AUC in the entire set at 1, 3 and 5 year was 0.85, 0.83 and 0.836. Our study provided a profile of relapse-associated ASs in I–III colon cancer and built a robust signature to predict the relapse of I–III colon cancer. •Relapse-associated alternative splicing (AS) in colon cancer were identified.•Potential interactions of relapse-associated ASs, relevant proteins, and splicing factors (SFs) were analyzed.•A robust signature was constructed in the training set.•The signature was validated to be efficient.